192 related articles for article (PubMed ID: 35575578)
1. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
[TBL] [Abstract][Full Text] [Related]
2. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).
Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Gilder E; Kim HS; Lim SY; McGuinness S; Parke R; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA;
Clin Pharmacokinet; 2022 Jun; 61(6):847-856. PubMed ID: 35253107
[TBL] [Abstract][Full Text] [Related]
4. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
[TBL] [Abstract][Full Text] [Related]
5. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients.
Leegwater E; Kraaijenbrink BVC; Moes DJAR; Purmer IM; Wilms EB
J Antimicrob Chemother; 2020 Jun; 75(6):1554-1558. PubMed ID: 32129853
[TBL] [Abstract][Full Text] [Related]
8. Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study.
Tsai D; Zam BB; Tongs C; Chiong F; Sajiv C; Pawar B; Ashok A; Cooper BP; Tong SYC; Janson S; Wallis SC; Roberts JA; Parker SL
J Antimicrob Chemother; 2023 Aug; 78(8):1963-1973. PubMed ID: 37367723
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection.
van den Broek AK; van Schip A; Visser CE; Bos JC; Prins JM; van Hest RM
Br J Clin Pharmacol; 2023 Nov; 89(11):3262-3272. PubMed ID: 37309251
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
[TBL] [Abstract][Full Text] [Related]
11. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment.
Tang Girdwood S; Dong M; Tang P; Stoneman E; Jones R; Yunger T; Ostermeier A; Curry C; Forton M; Hail T; Mullaney R; Lahni P; Punt N; Kaplan J; Vinks AA
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0142721. PubMed ID: 34633847
[TBL] [Abstract][Full Text] [Related]
14. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia.
Dreesen E; Gijsen M; Elkayal O; Annaert P; Debaveye Y; Wauters J; Karlsson MO; Spriet I
J Antimicrob Chemother; 2022 Aug; 77(9):2479-2488. PubMed ID: 35815604
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
16. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
[TBL] [Abstract][Full Text] [Related]
17. Ceftriaxone dosing in patients admitted from the emergency department with sepsis.
Heffernan AJ; Curran RA; Denny KJ; Sime FB; Stanford CL; McWhinney B; Ungerer J; Roberts JA; Lipman J
Eur J Clin Pharmacol; 2021 Feb; 77(2):207-214. PubMed ID: 32974748
[TBL] [Abstract][Full Text] [Related]
18. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
[TBL] [Abstract][Full Text] [Related]
19. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
